# Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers

> **NCT05597241** · PHASE1 · COMPLETED · sponsor: **Syndeio Biosciences, Inc** · enrollment: 40 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** apimostinel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05597241
- **Lead sponsor:** Syndeio Biosciences, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-15
- **Primary completion:** 2023-04-04
- **Final completion:** 2023-04-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2023-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05597241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05597241, "Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05597241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*